Department of Molecular Pharmacology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY, 10461, USA.
Neurochem Res. 2024 Nov;49(11):3006-3013. doi: 10.1007/s11064-024-04233-6. Epub 2024 Sep 5.
Glioblastomas are the most common primary malignant grade 4 tumors of the central nervous system (CNS). The treatment and management of such tumors requires a multidisciplinary approach and nuclear medicine techniques play an important role in this process. Glioblastoma, which recurs despite current treatments and becomes resistant to treatments, is among the tumors with the lowest survival rate, with a survival rate of approximately 8 months. Currently, the standard treatment of glioblastoma is adjuvant chemoradiotherapy after surgical resection. There have been many recent advances in the field of Nuclear Medicine in glioblastoma. PET scans are critical in determining tumor localization, pre-surgical planning, evaluation of post-treatment response and detection of recurrence. Advances in the treatment of glioblastoma and a better understanding of the biological characteristics of the disease have contributed to the development of nuclear medicine techniques. This review, in addition to other studies, is intended as a general imaging summary guide and includes some new expressions discovered in glioblastoma. This review discusses recent advances in nuclear medicine in glioblastoma.
胶质母细胞瘤是中枢神经系统（CNS）最常见的原发性恶性 4 级肿瘤。此类肿瘤的治疗和管理需要多学科方法，核医学技术在这一过程中发挥着重要作用。尽管目前的治疗方法使胶质母细胞瘤复发并产生抗药性，但它是存活率最低的肿瘤之一，存活率约为 8 个月。目前，胶质母细胞瘤的标准治疗是手术切除后的辅助放化疗。在胶质母细胞瘤的核医学领域，最近取得了许多进展。PET 扫描对于确定肿瘤定位、术前规划、评估治疗后反应和检测复发至关重要。胶质母细胞瘤治疗的进展和对疾病生物学特征的更好理解，促进了核医学技术的发展。除其他研究外，本综述旨在作为一般成像总结指南，包括在胶质母细胞瘤中发现的一些新表达。本文讨论了核医学在胶质母细胞瘤中的最新进展。
